What If FDA Clearance Was the Least Important Part of Your Product Launch?

Every MedTech company is obsessed with FDA clearance.

That's the problem.

We've convinced ourselves that regulatory approval is the hardest part of bringing a medical device to market. Years of R&D. Clinical studies. Regulatory submissions. Endless documentation. It feels like the finish line.

It isn't.

It's simply permission to compete.

The uncomfortable truth is this: FDA clearance doesn't create demand. It creates eligibility.

Hospitals don't buy FDA approvals.

Physicians don't change clinical practice because a device has regulatory clearance.

Procurement teams don't sign contracts because your press release announced another milestone.

Healthcare buyers buy something far more valuable.

Confidence.

Confidence that your technology improves patient outcomes.

Confidence that clinical evidence supports your claims.

Confidence that your company will still be innovating five years from now.

At Purple Crayon Brand, we've seen one pattern repeat itself across successful MedTech companies: the organizations that win don't start commercialization after FDA clearance—they start building trust long before it.

While competitors are focused on regulatory milestones, category leaders are already educating clinicians, collaborating with Key Opinion Leaders (KOLs), presenting at industry conferences, publishing thought leadership, and shaping conversations around the healthcare challenges they solve.

Expert Perspective

Jeff McClelland, CEO, Purple Crayon Brand

"FDA clearance is a regulatory milestone, not a commercialization strategy. The MedTech companies that achieve lasting market success are the ones that build credibility, educate healthcare buyers, and establish trust long before their product reaches the market. Regulatory approval may open the door, but market confidence determines who walks through it."

By launch day, they aren't introducing themselves to the market.

The market already knows them.

Research from Gartner consistently shows that B2B buyers spend most of their purchasing journey researching independently before ever speaking to a vendor. Healthcare buying journeys are even longer, involving clinicians, procurement teams, finance leaders, and executives, all evaluating trust, evidence, and long-term value before making a decision.

That's why commercialization isn't a launch activity.

It's a reputation strategy.

The MedTech companies that dominate tomorrow won't necessarily have the most innovative products.

They'll be the companies that become the most trusted voice in their category.

Because in healthcare, regulatory approval gets you into the market. Trust is what earns adoption.

Ready to Build Market Confidence Before Your Product Launch?

At Purple Crayon Brand, we help MedTech companies transform regulatory milestones into long-term commercial success through strategic positioning, thought leadership, and commercialization strategies that build credibility before the market starts evaluating your product.